Epifriedelanol
Based on 1 Customer Validation
Epifriedelanol is a triterpenoid found in the root bark of Ulmus davidiana. Epifriedelanol induces apoptosis in DU145 cells. Epifriedelanol has antitumor and anti-inflammatory activities. Epifriedelanol inhibits cellular senescence in human primary cells.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.69%
- CAS. Nr.: 16844-71-6
- Formel: C30H52O
- Molecular Weight:428.73
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | GI50 |
>100 μM
Compound: 9
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 11678649] |
| NCI-H460 | GI50 |
>100 μM
Compound: 9
|
Cytotoxicity against human NCI-H460 cells by SRB assay
Cytotoxicity against human NCI-H460 cells by SRB assay
|
[PMID: 11678649] |
| SF-268 | GI50 |
>100 μM
Compound: 9
|
Cytotoxicity against human SF268 cells by SRB assay
Cytotoxicity against human SF268 cells by SRB assay
|
[PMID: 11678649] |
| TK-10 | GI50 |
>100 μM
Compound: 9
|
Cytotoxicity against human TK10 cells by SRB assay
Cytotoxicity against human TK10 cells by SRB assay
|
[PMID: 11678649] |
| UACC-62 | GI50 |
>100 μM
Compound: 9
|
Cytotoxicity against human UACC62 cells by SRB assay
Cytotoxicity against human UACC62 cells by SRB assay
|
[PMID: 11678649] |
Epifriedelanol (40-60 μg/disc) shows significant in vitro antitumor properties in a potato disc bioassay study[1].
Epifriedelanol (10-50 μg/mL, 3 days) suppresses Doxorubicin (HY-15142A) (adriamycin)-induced cellular senescence as well as replicative senescence in HDFs and HUVECs[2].
Epifriedelanol (10-100 μg/mL, 5 h) represses the levels of p53 and p21 proteins increased by Adriamycin treatment in a dose-dependent manner[2].
Epifriedelanol (3-epifriedelinol) (0-50 μM, 24-72 h) inhibits DU145 and PC3 cells with IC50s of 32.32, and 35.22 μM, respectively at 72 h[3].
Epifriedelanol (5-10μM, 48 h) induces apoptosis in DU145 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human dermal fibroblasts (HDFs) and human umbilical vein endothelial cells (HUVECs)
-
Concentration:10, 30, 50 μg/mL
-
Incubation Time:3 days
-
Result:Inhibited senescence associated β-galactosidase (SA-β-gal) activity.
Had some cytotoxic effect in HUVECs but not in HDFs upon treatment with 50 µg/mL.
Decreased intracellular ROS levels augmented by adriamycin treatment.
Might be able to inhibit replicative senescence.
-
Cell Line:Human dermal fibroblasts (HDFs) and human umbilical vein endothelial cells (HUVECs)
-
Concentration:10, 30, 50, 100 μg/mL
-
Incubation Time:5 h (1 h prior to 500 nM adriamycin treatment, then incubation for 4 h)
-
Result:Repressed the levels of p53 and p21 proteins increased by adriamycin treatment in a dose-dependent manner.
-
Cell Line:DU145 (human prostate cancer cell line)
-
Concentration:5, 10μM
-
Incubation Time:48 h
-
Result:Showed enhanced caspase 3 cleavage and downstream PARP, upregulation of pro-apoptotic P53 and BAX while down-regulation of anti-apoptotic NF-κB and BCL2.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats, (180-200 g, age of 9-10 weeks)[3]
-
Dosage:5, 10 mg/kg
-
Administration:Oral gavage (p.o.); 21 days
-
Result:Showed a substantial decrease in prostate weight treated with Bisphenol A (BPA) (HY-18260), which could increase prostate size.
Did not exhibit any detectable alterations in hematologic parameters when compared to the control group, supporting its biosafety and application in in vivo systems.
Was preemptive against BPA-induced toxicity at both its high (10 mg/kg) and low (5 mg/kg) doses.
Effectively retained physiological serum estradiol concentrations in a dose-dependent manner.
Reduced peroxidation, and suppression of inflammatory markers (NO, IL-6 and TNF-α), indicating substantial antiinflammatory potential.
Chemical Information
-
CAS. Nr. 16844-71-6
-
Appearance Solid
-
Molecular Weight 428.73
-
Formel C30H52O
-
Color White to off-white
-
SMILES
C[C@]([C@](CC[C@@]1(C)[C@@]2([H])CC[C@H](O)[C@@H]1C)([H])[C@@]2(C)CC3)(CC[C@]4(C)[C@@]5([H])CC(C)(C)CC4)[C@@]35C
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Lösungsmittel & Löslichkeit
THF : 10 mg/mL (23.32 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
DMF : < 1 mg/mL (insoluble)
Ethanol : < 1 mg/mL (insoluble)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Acetone : < 1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Kundu JK, et al. Antitumor activity of epifriedelanol from Vitis trifolia. Fitoterapia. 2000 Sep;71(5):577-9. [Content Brief]
[2]. Yang HH, et al. Epifriedelanol from the root bark of Ulmus davidiana inhibits cellular senescence in human primary cells. Planta Med. 2011 Mar;77(5):441-9. [Content Brief]
[3]. Majid M, et al. Ameliorative Effect of Structurally Divergent Oleanane Triterpenoid, 3-Epifriedelinol from Ipomoea batatas against BPA-Induced Gonadotoxicity by Targeting PARP and NF-κB Signaling in Rats. Molecules. 2022 Dec 29;28(1):290. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| THF | 1 mM | 2.3325 mL | 11.6624 mL | 23.3247 mL | 58.3118 mL |
| 5 mM | 0.4665 mL | 2.3325 mL | 4.6649 mL | 11.6624 mL | |
| 10 mM | 0.2332 mL | 1.1662 mL | 2.3325 mL | 5.8312 mL | |
| 15 mM | 0.1555 mL | 0.7775 mL | 1.5550 mL | 3.8875 mL | |
| 20 mM | 0.1166 mL | 0.5831 mL | 1.1662 mL | 2.9156 mL |
Epifriedelanol Related Classifications
HY-N1931 Related Classifications
Powered by Bioz